Association of plasma concentration of 4α-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients

Drug Metabolism and Disposition

Volumn 42, Issue 1, 2014, Pages 105-110

  Suzuki, Yosuke ^a   Itoh, Hiroki ^a   Fujioka, Takashi ^a   Sato, Fuminori ^b   Kawasaki, Kanako ^a   Sato, Yukie ^a   Sato, Yuhki ^a   Ohno, Keiko ^c   Mimata, Hiromitsu ^b   Kishino, Satoshi ^c  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4BETA HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; CYTOCHROME P450 3A5; INDICAN; INDOLEACETIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CLINICAL ARTICLE; CREATININE CLEARANCE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JAPANESE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; HYDROXYCHOLESTEROLS; INDICAN; INDOLEACETIC ACIDS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84890753909     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054171     Document Type: Article

References (43)

1. Amundsen R, Åsberg A, Ohm IK, and Christensen H (2012) Cyclosporine A-and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab Dispos 40:655-661.
2. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, and Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 276:38685-38689.
3. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, and Diczfalusy U (2002) Metabolism of 4 beta-hydroxycholesterol in humans. J Biol Chem 277:31534-31540.
4. Calaf R, Cerini C, Génovésio C, Verhaeghe P, Jourde-Chiche N, Bergé-Lefranc D, Gondouin B, Dou L, Morange S, and Argilés A, et al. (2011) Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. J Chromatogr B Analyt Technol Biomed Life Sci 879:2281-2286.
5. Cockcroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
6. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, and Kim JW, et al. (2008) 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18:201-208. (Pubitemid 351323234)
7. Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, and Bertilsson L (2009) 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 67:38-43.
8. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, and Henrich WL (2003) Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73:427-434. (Pubitemid 36549827)
9. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, and Azuma J (2002) Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12:331-334. (Pubitemid 34620661)
10. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, and Kasuya Y (2003) Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 31:1283-1287. (Pubitemid 37310312)
11. Galteau MM and Shamsa F (2003) Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59:713-733. (Pubitemid 38041296)
12. Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, and Bifano M, et al. (2011) Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol 24:1575-1585.
13. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, and Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14:471-478. (Pubitemid 38971237)
14. Guévin C, Michaud J, Naud J, Leblond FA, and Pichette V (2002) Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 137: 1039-1046. (Pubitemid 35440744)
15. Hanada K, Ogawa R, Son K, Sasaki Y, Kikkawa A, Ichihara S, and Ogata H (2006) Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron, Physiol 103:179-186.
16. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, Kishikawa Y, Matsuura M, Agatsuma Y, Inoue T, and Mizugaki M (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58:417-421.
17. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304. (Pubitemid 46174829)
18. Huang WH, Hung CC, Yang CW, and Huang JY (2012) High correlation between clearance of renal protein-bound uremic toxins (indoxyl sulfate and p-cresyl sulfate) and renal water-soluble toxins in peritoneal dialysis patients. Ther Apher Dial 16:361-367.
19. Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, and Diczfalusy U (2008) CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol 64: 775-781.
20. Kagaya H, Miura M, Satoh S, Inoue K, Saito M, Inoue T, Habuchi T, and Suzuki T (2008) No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. J Clin Pharm Ther 33:193-201. (Pubitemid 351341413)
21. Karayalçin U, Takeda Y, Miyamori I, Morise T, and Takeda R (1991) Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: a preliminary study. Steroids 56:598-600.
22. Kirwan CJ, Lee T, Holt DW, Grounds RM, MacPhee IA, and Philips BJ (2009) Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 35: 1271-1275.
23. Kirwan CJ, MacPhee IA, Lee T, Holt DW, and Philips BJ (2012) Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med 38:76-84.
24. Klein K and Zanger UM (2013) Pharmacogenomics of cytochrome P450 3A4: Recent progress toward the "missing heritability" problem. Front Genet 4:1-15.
25. Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, and Yamaji A (2004) Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharm Pharmacol 56:1259-1266. (Pubitemid 39368996)
26. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, and Jorkasky DK (1998) Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 63:617-622. (Pubitemid 28327888)
27. Kusaba J, Kajikawa N, Kawasaki H, Kurosaki Y, and Aiba T (2012) Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure. Biopharm Drug Dispos 33:22-29.
28. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, and Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132. (Pubitemid 34298916)
29. Lütjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T, Björkhem I, and Diczfalusy U (2009) 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo-effects of itraconazole in man. Int J Clin Pharmacol Ther 47:709-715.
30. Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J, and Pichette V (2008) Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 108:157-163.
31. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, Tanaka M, Inoue M, and Yokoi T (2005) Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 45:674-682. (Pubitemid 40696210)
32. Niemi M, Kivistö KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, and Eichelbaum M (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharma-cogenet Genomics 16:565-568. (Pubitemid 44100201)
33. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, and Himmelfarb J (2006) Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17:2363-2367. (Pubitemid 44300952)
34. Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, and Himmelfarb J (2009) ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 20: 2269-2276.
35. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, and Yamazaki H (2013) The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 38:349-354.
36. Rege B, Krieg R, Gao N, and Sarkar MA (2003) Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm Res 20:1600-1606. (Pubitemid 37268275)
37. Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, Komamura K, Ueno K, Kamakura S, and Nakajima T, et al. (2003) Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 21:1-7.
38. Streetman DS, Bertino JS, Jr, and Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187-216. (Pubitemid 30242736)
39. Suzuki Y, Itoh H, Sato F, Kawasaki K, Sato Y, Fujioka T, Sato Y, Ohno K, Mimata H, and Kishino S (2013) Significant increase in plasma 4-hydroxycholesterol concentration in patients after kidney transplantation. J Lipid Res 54:2568-2572.
40. Velenosi TJ, Fu AY, Luo S, Wang H, and Urquhart BL (2012) Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease. Drug Metab Dispos 40:1508-1514.
41. Wide K, Larsson H, Bertilsson L, and Diczfalusy U (2008) Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Pharmacol 65:708-715. (Pubitemid 351535081)
42. Yamamoto T, Nagafuchi N, Ozeki T, Kubota T, Ishikawa H, Ogawa S, Yamada Y, Hirai H, and Iga T (2003) CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 18:267-268.
43. Zanger UM, Turpeinen M, Klein K, and Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.